Table 1.
Clinical characteristics of study population
| Characteristic | Total (n = 303) | Australia (n = 210) | Oxford (n = 93) | |
| Gender | ||||
| Female, n (%) | 143 (47) | 95 (45) | 48 (52) | |
| Median age VDZ given (range, yr) | 35 (16-84) | 36 (19-78) | 35 (16-84) | |
| Median disease duration (range, yr) | 6 (0.2-48) | 7 (1-48) | 5.4 (0.2-39.2) | |
| Montreal classification, n (%) | ||||
| Age | ||||
| A1 | 34 (11) | 33 (16) | 1 (1) | |
| A2 | 170 (56) | 120 (57) | 50 (54) | |
| A3 | 99 (33) | 57 (27) | 42 (45) | |
| Location | ||||
| E1 | 18 (6) | 15 (7) | 3 (3) | |
| E2 | 114 (38) | 72 (34) | 42 (45) | |
| E3 | 170 (56) | 122 (58) | 48 (52) | |
| Missing | 1 | 1 | 0 | |
| Family History, n (%) | 29 (12) | 22 (15) | 7 (7) | |
| First degree | 19 | 12 | 7 | |
| Second degree | 10 | 10 | 0 | |
| None | 212 | 126 | 86 | |
| Smoking, n | ||||
| Never | 226 | 140 | 86 | |
| Current | 9 | 6 | 3 | |
| Ex smoker | 45 | 41 | 4 | |
| Anti-TNF naïve, n (%) | 182 (60) | 122 (58.1) | 60 (65) | |
| Anti-TNF exposed, n (%) | 121 (40) | 88 (41.9) | 33 (35) | |
| Primary LOR | 45 (15) | 29 (13.8) | 16 (17) | |
| Secondary LOR | 61 (20) | 47 (22.4) | 14 (15) | |
| Side-effects | 15 (5) | 12 (5.7) | 3 (3.2) | |
| Steroids at VDZ initiation, n (%) | 191 (63) | 134 (64) | 57 (61.2) | |
| Prednisone | 162 (53) | 108 (51) | 54 (58) | |
| Budesonide | 29 (10) | 26 (12) | 3 (3) | |
| Immunomodulation at VDZ initiation, n (%) | 175 (58) | 135 (64) | 40 (43) | |
| AZA/6MP | 136 (45) | 108 (51) | 28 (30) | |
| Methotrexate | 19 (6) | 11 (5) | 8 (9) | |
| Tacrolimus | 17 (6) | 16 (8) | 1 (1) | |
| Others (Cyclo&Myco) | 3 (1) | 0 | 3 (3) | |
| Mean Partial Mayo before VDZ initiation | 5 (2-9) | 6 (2-9) | 5 (2-9) | |
VDZ: Vedolizumab; min: Minimum; max: Maximum; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response; Secondary LOR: Secondary loss of response; AZA: Azathioprine; 6MP: 6-mercaptopurine; Cyclo: Ciclosporine; Myco: Mycophenolate; Init, Initiation.